Nodal Pathologic Response to Neoadjuvant Systemic Therapy in Clinical N2 and N3 Nonmetastatic Breast Cancer

Diana M Jaen1, Collin E Dougherty1, Kimberly A Helseth1

  • 1Division of Surgical Oncology, Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska.

Summary

Over 40% of patients with advanced breast cancer (cN2/cN3) achieved a complete response in lymph nodes after neoadjuvant systemic therapy (NST). Factors like HER2-positive status and complete breast response (ypT0) predict nodal response, aiding surgical de-escalation decisions.

Related Concept Videos